Jordana Jampel

DocwireNews

A study led by Deepak Kumar and <a href="https://www.cureus.com/articles/145390-evaluation-of-tumor-infiltrating-lymphocytes-as-predictors-of-response-to-neoadjuvant-chemotherapy-in-patients-with-locally-advanced-breast-cancer#!/" target="_blank" rel="noopener">published</a> in Cureus aimed to evaluate tumor-infiltrating lymphocytes (TILs) as predictors of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer (LABC).Thirty-five patients with LABC were included in the study. Demographics, medical history, and signs and symptoms data were collected for each patient. The cohort underwent a complete clinical evaluation involving physical examination, imaging studies (mammogram/ultrasound imaging) biopsy, and metastatic workup.The patients consented to core-needle biopsy under local anesthesia followed by a pathologic assessment of breast cancer type before neoadjuvant chemotherapy and after mastectomy.Patients treated with neoadjuvant chemotherapy were followed up for response using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and were scheduled for modified radical mastectomy (MRM) after neoadjuvant chemotherapy completion. MRM specimens were sent in for CD3 and CD5 immunohistopathologic analysis; correlations between TILs and grading with NACT response and type of cancer were analyzed.Twenty-four of the 35 participants were positive for CD3. The researchers also identified a correlation between neoadjuvant chemotherapy for LABC treatment and CD3 TILs: 68.6% of participants were CD3-positive, with 54.3% showing stromal CD3 variants and 14.3% showing intramural CD3 variants. These results indicate that CD3 TILs may have prognostic value for response probability to neoadjuvant chemotherapy.In this participant sample:<ul>
<li>17 (48.6%) patients were CD5-positive with stromal predominance.</li>
<li>17 (48.6%) patients had a RECIST 1.1 complete response rate to neoadjuvant chemotherapy.</li>
<li>16 (45.7%) patients had a RECIST 1.1 partial response to neoadjuvant chemotherapy.</li>
<li>1 (2.9%) patient had progressive disease.</li>
</ul>The study shows a significant response to neoadjuvant chemotherapy in patients with LABC (P&lt;.0001). These results indicate that tumor size could be effectively evaluated using RECIST 1.1 criteria and that TILs can serve as a promising prognostic marker to evaluate response to neoadjuvant chemotherapy and immunologic response in breast and other types of cancers after chemotherapy treatment.

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Tumor-Infiltrating Lymphocytes Can Predict Response to Neoadjuvant Chemo in Locally Advanced Breast Cancer

Breast Cancer News

A study aimed to assess TILs as predictors of response to neoadjuvant chemotherapy in locally advanced breast cancer. 

Tumor-Infiltrating Lymphocytes Can Predict Response to Neoadjuvant Chemo in Locally Advanced BC

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe